A validated chiral HPLC method for the enantiomeric purity of alogliptin benzoate

Similar documents
Method Development and Validation for the Estimation of Darunavir in Rat Plasma by RP-HPLC

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

ISSN : A validated chiral LC method for enantiomeric separation of levocetrizine using protein based chiral stationary phase

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Simultaneous Estimation of Residual Solvents (Isopropyl Alcohol and Dichloromethane) in Dosage Form by GC-HS-FID

Enantiomeric separation of 1, 2, 3, 4-tetrahydro-1-naphthoic acid using chiral stationary Phase

SIMPLE AND SENSITIVE VALIDATED REVERSE PHASE HPLC-UV METHOD FOR THE DETERMINATION OF LYMECYCLINE IN PHARMACEUTICAL DOSAGE FORMS

Development and validation a RP-HPLC method: Application for the quantitative determination of quetiapine fumarate from marketed bulk tablets

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

Volume 6, Issue 2, January February 2011; Article-015

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR QUANTITATIVE ANALYSIS OF GABAPENTIN IN PURE AND PHARMACEUTICAL FORMULATIONS

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

Journal of Chemical and Pharmaceutical Research, 2012, 4(6): Research Article. Estimation of zaleplon by a new RP-HPLC method

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Pelagia Research Library

A VALIDATED LC METHOD FOR DETERMINATION OF THE ENANTIOMERIC PURITY OF ATORVASTATINM DRUG AND DOSAGE FORMS

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

Journal of Chemical and Pharmaceutical Research

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Novus International Journal of Analytical Innovations 2012, Vol. 1, No. 3

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Trace analysis of mesityl oxide and diacetone alcohol in pharmaceuticals by capillary gas chromatography with flame ionization detection

Determination of Fexofenadine Hydrochloride in Pharmaceutical Dosage Form By Reverse Phase High Performance Liquid Chromatography Method

Department of Chemistry, JNTUACE, Kalikiri

Impact factor: 3.958/ICV: 4.10 ISSN:

Available online Research Article

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

International Journal of Pharmacy and Pharmaceutical Sciences Vol 2, Issue 1, 2010

A Stability Indicating UPLC Method for Candesartan in Bulk Drug Samples

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

ChromegaChiral TM CSP Media and Columns

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

Zero And First Order Derivative Spectrophotometric Methods For Determination Of Dronedarone In Pharmaceutical Formulation

Development and Validation of Sensitive RP-HPLC Method for the Estimation of Glibenclamide in Pure and Tablet Dosage Forms

Research Article. Identification and characterization of unknown impurity in zolmitriptan tablets by a sensitive HPLC method

Radhakrishnan K. et al. / International Journal of Pharmacy & Therapeutics, 3(1), 2012, e- ISSN Print ISSN

CHAPTER 1 Role of Bioanalytical Methods in Drug Discovery and Development

Journal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters

Pharmacophore 2011, Vol. 2 (4), ISSN Pharmacophore. (An International Research Journal)

Development and validation of RP-HPLC method for the analysis of carbofuran and in its formulations

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

Development and Validation of Chiral LC Method for the Enantiomeric Separation of Duloxetine on Amylose Based Stationary Phase

Appendix II- Bioanalytical Method Development and Validation

Available online at Scholars Research Library

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

SIMULTANEOUS ESTIMATION OF MEFENAMIC ACID AND PARACETAMOL IN SUSPENSION FORM BY USING UPLC

Department of Quality Assurance, Luqman College of Pharmacy, GULBARGA (K.S.) INDIA ABSTRACT

Research Article Available online at

Received: ; Accepted:

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Atovaquone

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

A SIMPLE RP-HPLC METHOD FOR QUANTITATION OF CARBOPROST TROMETHAMINE IN INJECTION DOSAGE FORM

Journal of Chemical and Pharmaceutical Research, 2017, 9(10): Research Article

Development of RP-HPLC method for estimation of Olmesartan Medoxomil in tablet dosage forms

Pelagia Research Library

Low-level Determination of 4-Hydrazino Benzoic Acid in Drug Substance by High Performance Liquid Chromatography/Mass Spectrometry

Isocraticc Reverse Phase HPLC Method-Determination and Validation of Cilostazol

Journal of Chemical and Pharmaceutical Research

ChromegaChiral TM CSP Media and Columns

Chapter 4: Verification of compendial methods

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

Journal of Chemical and Pharmaceutical Research

Development and validation of RP-LC method for lisinopril dihydrate in bulk and its pharmaceutical formulations

Available online at Scholars Research Library

Analysis of PEGylated Proteins with Agilent AdvanceBio SEC Columns

Praveen kumar.m 1 *, Sreeramulu.J 2. *Corres.author: Mobile no: India.

A Novel Stability Indicating Chromatographic Method Development And Validation For The Quantification of Tofacitinib In Pure And Its Dosage Form

CHAPTER-4. determination of chiral purity of (S)-2azido-3-methylbutanoic acid: a key raw. material of Valganciclovir hydrochloride

DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING RP-HPLC METHOD FOR ASSAY OF IRBESARTAN IN PURE AND PHARMACEUTICAL DOSAGE FORM

Development and validation of UV- spectrophotometric method for the estimation of dabigatran etexilate mesylate (dem)

Development And Validation Of Stability Indicating RP-HPLC Method For Estimation Of Ledipasvir And Sofosbuvir

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

RP-HPLC Estimation of Trospium Chloride in Tablet Dosage Forms

Scholars Research Library. Rapid and sensitive RP-HPLC analytical method development and validation of Pioglitazone hydrochloride

Journal of Chemical and Pharmaceutical Research, 2013, 5(5): Research Article

637. Thiamethoxam. HPLC method

RP-HPLC Method Development and Validation for Estimation of Triamcinolone Acetonide in Injectable Suspension using USP-Type-IV Dissolution Apparatus

STABILITY INDICATING RP HPLC METHOD FOR ANALYSIS OF DORZOLAMIDE HCl IN THE BULK DRUG AND IT S PHARMACEUTICAL DOSAGE FORM

Simultaneous estimation and validation of bromhexine and cephalexin in bulk and pharmaceutical dosage form by RP-HPLC method

SIMULTANEOUS RP HPLC DETERMINATION OF CAMYLOFIN DIHYDROCHLORIDE AND PARACETAMOL IN PHARMACEUTICAL PREPARATIONS.

Scholars Research Library

H 3 CO H 3 CO S CH 3

Journal of Advanced Scientific Research DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP-HPLC METHOD FOR ESTIMATION OF DABIGATRAN ETEXILATE

Research Article. Figure 1. Chemical structure of doxofylline. Indonesian J. Pharm. Vol. 24 No. 1 : ISSN-p :

J Pharm Sci Bioscientific Res (4): ISSN NO

HPLC Method Development and Validation for the estimation of Esomeprazole in Bulk and Pharmaceutical Dosage Form

Transcription:

Available online at www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 214, 6(3):234-239 (http://derpharmachemica.com/archive.html) ISS 975-413X CDE (USA): PCHHAX A validated chiral HPLC method for the enantiomeric purity of alogliptin benzoate G. Srinivasa Rao 1, K. Mallesh 2, G. Vijay Kumar 2, Ch. Surekha 1 and B. Venugopala Rao 2* 1 Department of Biochemistry, GIS, GITAM University, Visakhapatnam, Andhra Pradesh, India 2 Dissymmetrix Private Limited. Plot o-36/a, IDA, UPPAL, Hyderabad, Andhra Pradesh, India ABSTRACT An isocratic chiral stationary phase high-performance liquid chromatographic (CSP-HPLC) method has been developed and validated for the quantitation of (S)-isomer in Alogliptin Benzoate. Separation was achieved with a Lux cellulose 2 (25 4.6mm, 5µm) column. The ratio of ethanol and diethyl amine in the mobile phase were optimized to obtain the best separation. UV detection was performed at 23 nm. The described method is linear over a range of LQ 1.5 µg/ml of (S)-isomer. The mean recovery of (S)-isomer was found to be in the range of 1 12%. The method is simple, rapid, accurate, selective and precise, useful in the quality control of bulk manufacturing. Keywords: Chiral Separation, Alogliptin, (S)-isomer, Enantiomeric purity, Validation. ITRDUCTI Alogliptin is an orally administered anti-diabetic drug in the DPP-4 inhibitor class. Molecular Formula C 18 H 21 5 2 and IUPAC name 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4- dihydropyrimidin-1(2h)- yl}methyl) benzonitrile. Separation of enantiomers has become very important in analytical chemistry, especially in the pharmaceutical and biological fields, because some stereoisomers of racemic drugs have quite different pharmacokinetic properties and different pharmacological or toxicological effects [1-2]. This is one of the most vital reasons why the regulatory authorities insist more on stringent investigation for evaluating the safety and the effectiveness of drugs containing chiral centers. Most of the pharmaceutical industries are now concentrating towards the study of the therapeutic effect of pure enantiomers of the existing drug molecules. Enantiomeric separations have acquired importance in all the stages of drug development and the commercialization process. A control and accurate quantification of undesired enantiomers in Active Pharmaceutical Ingredient is essential [3], therefore, the development of new methods for efficient chiral separations mainly based on HPLC, capillary electrophoresis (CE) or gas chromatography (GC) is more than necessary. Among the chromatographic methods so far developed, HPLC methods based on chiral stationary phases are widely employed for the assays of drug isomers in pharmaceutical preparations and biological fluids. To the best of our knowledge no chiral HPLC method is reported in the literature for the enantiomeric separation of alogliptin isomers. Therefore, the aim of this study is to develop a chiral HPLC method for the determination of enantiomeric purity by accurate quantification of un-required (S)-isomer of alogliptin and validate as per the ICH guideline [4]. 234

B. Venugopala Rao et al Der Pharma Chemica, 214, 6 (3):234-239 MATERIALS AD METHDS Chemicals and reagents Samples of alogliptin benzoate and (S)-isomer (Fig. 1) were synthesized at Dissymmetrix laboratory, Hyderabad, India. HPLC grade ethanol is obtained from Brampton, ntario L6T 3Y4 (Canada). Analytical grade diethyl amine (DEA) is purchased from Merck (India). LC grade water was deionized with Milli-Q Elix and then filtered using Milli-Q gradient, Millipore water purification system (USA). Equipment The HPLC system consisted of quaternary gradient pump, auto sampler, column oven and a variable wavelength detector. The output signal was monitored and integrated using EZ-Chrom Elite Chromatography Data Software (12 series HPLC, Agilent, USA). Preparation of standard solutions Dissolved an accurately weighed quantity of (S)-isomer working standard in minimum quantity of ethanol and made up with mobile phase to obtain a solution having known concentration of about.1 mg/ml and injected in to the system. Dissolved an accurately weighed quantity of alogliptin benzoate sample in minimum quantity of ethanol and made up with mobile phase to obtain a solution having known concentration of about.2 mg/ml and injected in to the system. Chromatographic conditions A Lux Cellulose-2 chiral stationary phase analytical column (25 mm 4.6 mm, 5µm packing) (Phenomenex India Pvt Ltd) was used. A mixture of ethanol and DEA in the ratio of 1:.5 (v/v) was used as mobile phase. It was filtered through a.45µm-nylon membrane using a Millipore vacuum filtration system. The mobile phase was pumped through the column at a flow rate of 1. ml/min. The sample injection volume was 2µL. The detector was set to a wavelength of 23 nm. RESULTS AD DISCUSSI Method Development To achieve separation between enantiomers of Alogliptin benzoate, chiral stationary phases (CSPs) containing cellulose and amylose derivatives were evaluated with suitable mobile phase compositions. The chiral discrimination of enantiomers occurs when they bind with the stationary phase forming transient diastereomeric complexes. The most important interactions between the analyte and the CSP are hydrogen bonding, dipole dipole interactions, and pi pi interactions, together with the rigid structure (Cellulose-based CSP) or helical structure (Amylose-based CSP) of the chiral polymer bound to the support. Various combinations of n-hexane: 2-propanol and n-hexane: ethanol was used as the mobile phase in our initial efforts in the normal-phase separation. These trials were made initially in the absence of DEA and then by adding DEA to the mobile phase. Attempts to separate the enantiomers on cellulose carbamate derivertized columns in normal-phase proved futile. Even with the use of Amylose ester derivertized columns the enantiomers could not be separated. The enantiomers could be separated only on Cellulose carbamate derivertized CSP (Lux Cellulose 2, 25mm length, 4.6 mm internal diameter and 5µm particle size) with mobile phase comprising Ethanol and DEA or n-hexane, ethanol and DEA. Various experiments were conducted, to select the best combination of stationary and mobile phase that could give optimum resolution and selectivity for the enantiomers. o separation was achieved on Lux Amylose 2, Daicel Chiralpak AD 3 columns. Very good separation was achieved on Lux Cellulose 2 with resolution of 4.55. In the case of CSPs with carbamate derivatives, binding of solute to the CSPs is achieved through the interactions between the solutes and the polar carbamate groups on CSPs. Solutes can bind to the carbamate groups on the CSPs forming transient diastereomers through hydrogen bonding using the C and H groups and also through dipole dipole interaction using the C moiety. Alogliptin benzoate has H and C (carbonyl) functional groups and these could well be contributing to the interactions with the carbamate groups on CSP, resulting in separation. The aromatic ring on the solute could provide additional stabilizing effect to the solute CSP complex as reported by Wainer et al. The use of ethanol in mobile phase provided better selectivity and resolution than 2-propanol. A comparison of the System suitability results obtained using ethanol and 2-propanol clearly indicate ethanol is the solvent of choice. The addition of DEA up to.1% (by volume) to the mobile phase resulted in improved peak shapes, better resolution and shorter run times. The effect of ethanol concentration, DEA concentration, temperature and flow rate on resolution (RS), retention time (t R ) and selectivity (α) were examined and the most optimum conditions were found to be a mobile phase consisting of ethanol: diethyl amine (1.:.5, v/v/v) at flow rate of 1. ml/min with the column maintained at ambient temperature. The method validation was carried out on the same. The enantiomeric separation of alogliptin benzoate on Chiralpak AD-3, Amylose-2 and Lux 235

B. Venugopala Rao et al Der Pharma Chemica, 214, 6 (3):234-239 cellulose 2 columns is shown in Fig. 2. Table 1: Accuracy results for (S)-isomer. (S)-isomer spike level (%, m/m) Added (µg) (n=3) Recovered (µg) % Recovery.25 25.6.5 5.12.75 75.18 25.1 1.2 25.5 1. 25.16 1.4 51.21 12.2 51.5 11.9 51.14 12. 75.85 1.9 75.94 11. 76.18 11.3 Mean Recovery %RSD 95% Confidence interval 1.2 1 ±.2 12.15 12 ±.2 11.21 11 ±.2 Table 2: Precision results for (S)-isomer. Repeatability Mean of (S)-isomer content (%, m/m) (n=6).153 Standard deviation (SD).5 %RSD 3.4 Intermediate Precision Analyst-1/Day-1 Mean of (S)-isomer content (%, m/m) (n=6).152 Standard deviation (SD).4 %RSD 2.7 Analyst-2 Mean of (S)-isomer content (%, m/m) (n=6).148 Standard deviation (SD).4 %RSD 2.8 verall %RSD (n=12) 2.8 Day-2 Mean of (S)-isomer content (%, m/m) (n=6).152 Standard deviation (SD).4 %RSD 2.7 verall %RSD (n=12) 2.6 Quantification of (S)-isomer Known concentration of standard solution (.1mg/mL) was used for the quantification of (S)-isomer in alogliptin benzoate sample (.2 mg/ml). ot more than.5%m/m of (S)-isomer is found in alogliptin benzoate. Method Validation Specificity Alogliptin benzoate and (S)-isomer were injected separately to confirm the retention times. System suitability solution was then injected. (S)-isomer and alogliptin benzoate peaks are eluted at 11.55 minutes and 15.43 minutes respectively (relative retention.75). The resolution between the peaks was found to be 4.55. The asymmetry for (S)-isomer and alogliptin peaks are 1.1 and 1.2 respectively. Linearity Standard solutions at ten different concentration levels ranging from.5,.1,.2,.3,.4,.5,.75, 1., 1.25 and 1.5µg/mL were prepared (.25.75% of analyte concentration of.2 mg/ml). Each sample solution was injected in triplicate. The mean responses recorded were plotted against concentration. The correlation coefficient for (S)-isomer was found to be.9998, which indicated good linearity. The calibration equation for (S)-isomer was found to be y = 16716x + 132. Accuracy Alogliptin benzoate sample was spiked with (S)-isomer at.25,.5 and.75% of analyte concentration of.2 mg/ml. Each spiked solution was prepared in triplicate and injected. The mean recoveries, recovery percentage and %RSD were calculated. The mean recoveries of (S)-isomer at each spike solution with 95% confidence interval are found to be 1±.2%, 12±.2% and 11±.2% respectively. Accuracy results are shown in Table 1. The acceptance criteria for recovery at each level are between 8 and 12% as per in-house validation protocol. 236

B. Venugopala Rao et al Der Pharma Chemica, 214, 6 (3):234-239 Fig. 1 Structural formula for Alogliptin benzoate (R) and (S)-isomer H 2 H Alogliptin Benzoate (R)_isomer H 2 H Alogliptin benzoate (S)_ isomer Precision Repeatability was demonstrated by injecting six individual spiked test preparations of alogliptin benzoate (.2mg/mL). Intermediate precision was demonstrated by analyzing same preparations of alogliptin benzoate by two different analysts on two different days. Intra-day variations of (S)-isomer content in alogliptin benzoate are expressed in terms of %RSD values. The values calculated were found to be 3.4% for repeatability, 2.8% and 2.7% for intermediate precision. Repeatability and intermediate precision results are shown in Table 2. Limit of Detection and Limit of Quantification The limit of detection and limit of quantification for (S)-isomer was calculated from the linearity data using residual standard deviation of the response and slope of the calibration curve. A typical S/ ratio of 2-3 and 9-1 are generally considered to be acceptable for LD and LQ respectively. LD and LQ values are found to be.16µg/ml and.354µg/ml respectively. Robustness In order to demonstrate the robustness of the method, chromatographic conditions were deliberately altered and the resolution was checked between (S)-isomer and alogliptin peaks. To study the effect of variation of flow rate on the resolution,.1 units of flow were changed from 1. ml min -1 (i.e..9 and 1.1 ml min -1 ). The effect of column temperature on resolution was studied at 2 and 35 o C instead of 25 o C. In all the above varied conditions, the composition of the mobile phase was held constant as those of the initial condition. In all the deliberate varied chromatographic conditions carried out (flow rate and temperature) the resolution between (S)-isomer and alogliptin was greater than 3., illustrating the good robustness of the method. 237

B. Venugopala Rao et al Der Pharma Chemica, 214, 6 (3):234-239 Fig. 2: Typical chromatograms of enantiomeric separation of racemic alogliptin on Lux Amylose 2, Chiralpak AD 3, Lux Cellulose 2 columns; mobile phase composed of ethanol: DEA (1:.5, v/v); flow rate 1. ml/min; UV-23 nm Column: Chiral Amylose-2 4 DAD-A:275nm Retention Time 4 3 3 2 2 1 1 1.14 5 1 15 2 25 3 Minutes Column: Chiralpak AD-3 5 DAD-A:295nm Retention Time 5 4 4 3 3 2 2 1 1 1.482 5 1 15 2 25 3 Minutes Column: Lux Cellulose-2 3 D A D -A :2 2 5 n m R e te n tio n T im e a m e 3 2 5 2 5 2 2 1 5 1 5 1 5 11.55 S-ALGLIPTI BEZATE 15.43 R-ALGLIPTI BEZATE 1 5. 2.5 5. 7.5 1. 1 2.5 1 5. 1 7.5 2. 2 2.5 M in u te s 238

B. Venugopala Rao et al Der Pharma Chemica, 214, 6 (3):234-239 Batch Analysis The (S)-isomer content in three different batch samples of alogliptin benzoate was determined and found to be less than.5% m/m. ther related substances were evaluated by a reverse phase HPLC method, known and unknown impurities (any other impurity) are less than.1% and total impurities are less than 1.% (excluding (S)-isomer content by chiral stationary phase HPLC). Stability in solution Standard solutions of (S)- Alogliptin Benzoate and (R)- Alogliptin Benzoate were prepared in the mobile phase at analyte concentration. Each standard solution was analyzed immediately after preparation (Fig. 4a and b) and divided into two parts. ne part was stored at 2 8 C in a refrigerator and the other at bench top in tightly capped volumetric flasks. The stored solutions of each isomer were reanalyzed after 24 h. o change in either the chemical or enantiomeric purity was observed. The area obtained for each isomer after 24 h did not show any significant change compared with the area of initial analysis. This indicates that both isomers were stable in the mobile phase for at least 24 h when stored either at 2 8 C or at bench top. CCLUSI A chiral HPLC method for the separation of Alogliptin Benzoate enantiomers was developed and validated. The chiral separation was achieved in cellulose carbamate derivertized column (Lux Cellulose-2). This method is simple, accurate and has provided good linearity, precision and reproducibility. The results of analysis obtained with this HPLC method and a validated CE method are comparable. The practical applicability of this method was tested by analyzing various batches of the bulk drug and formulations of Alogliptin Benzoate. Acknowledgements The authors wish to thank the management of GITAM University & Dissymmetrix Private Limited for supporting this work. REFERECES [1] 1. FDA policy statement for the Development of ew Stereoisomeric Drugs, Washington DC (1992). [2] 2. E.J. Ariens, E.W. Wuins, Clin. Pharmacol. Ther., 42, 361 (1987) [3] 3. G. Sridhar, R. Pramod Kumar, M.K. Srinivasu, Sangaraju Sivaiah, K.B.Chandrasekhar, B.M. Rao, Analytical Chemistry: An Indian Journal, 6, 35 (27) [4] 4. ICH Q2(R1), Guidelines on Validation of Analytical Procedures: Text and methodology, (25). 239